What usually decides whether bracing is enough

In practical terms, bracing is usually enough only when the main aim is to unload one side of the knee and settle symptoms. An unloader brace works by applying an external varus or valgus force to shift pressure away from the affected compartment, which can reduce pain and improve function, especially in unicompartment overload patterns. It does not, however, change the underlying alignment in the way surgery can. When medial-compartment symptoms persist despite good non-surgical management, high tibial osteotomy is the usual step-up because it corrects the load path itself. In a 2025 randomised trial of adults aged 18–65 with symptomatic medial compartment osteoarthritis, HTO gave better 12-month pain outcomes than a valgus unloader brace, with a KOOS pain difference of -28 points in favour of HTO.

The picture changes again when imaging shows a discrete cartilage lesion. At that point, the question is no longer only whether load can be shifted, but whether the defect itself is suitable for repair in a knee with acceptable mechanics. ChondroFiller sits in that focal-restoration lane: clinic and manufacturer-facing sources describe it for selected patients with focal cartilage defects, with the evidence base most mature in the knee, not as a blanket treatment for every painful arthritic knee. In practice, these options are complementary rather than interchangeable: some knees respond to offloading, some need alignment correction first, and some may then be considered for focal defect repair.

When an unloader brace is worth trying

A brace tends to be most useful when symptoms clearly come from one overloaded part of the knee rather than a knee that is globally worn out. In the 2012 review of off-loader bracing, the best-supported pattern was unicompartment osteoarthritis, particularly when pain rises with walking, standing, stairs or sport and there is still a realistic joint-preservation window. In that setting, bracing may offer symptom relief and better day-to-day function while physiotherapy continues, or while a patient weighs up whether a larger procedure is justified. The realistic aim is load redistribution and pain control, not cartilage regrowth.

That trial is most meaningful when the brace is matched to the knee, fitted properly, and worn consistently during load-bearing activities rather than only tried on briefly at home. The same review noted benefit in some patients with unicompartment disease plus “mild to moderate instability”, with improvements in pain, stability and fall risk, but only when the underlying pattern has been identified correctly. A useful review point after a few weeks is practical rather than theoretical: is walking easier, are stairs less provocative, and is function better enough to justify continuing? If those gains do not appear, bracing is less likely to be the right long-term answer on its own.

When osteotomy becomes the better next step

Persistent pain after a sensible trial of brace wear and physiotherapy is usually the point where the question changes. In the 2025 randomised trial of adults aged 18–65 with symptomatic medial compartment knee osteoarthritis, high tibial osteotomy (HTO) produced better pain outcomes at 12 months than a valgus unloader brace. The clearest head-to-head evidence therefore supports stepping up when examination and imaging keep showing a correctable alignment pattern driving the same compartmental overload, rather than continuing indefinitely with a device that only helps while it is being worn. Most of that direct evidence comes from medial-compartment osteoarthritis, so the same logic still has to be checked against the exact defect location, alignment and arthritis stage in other knees.

In practice, HTO tends to suit a narrower group: younger, active patients with symptomatic unicompartment disease who are still reasonable joint-preservation candidates. Long-term data suggest that, for the right profile, it may buy meaningful time before replacement rather than simply shifting symptoms for a few months: a 2024 systematic review reported average HTO survivorship of 74.6% at 10 years, and a 20-year series found the strongest results in patients under 55 who were not obese and not yet severely disabled. The trade-off is that this is bone surgery, not a brace adjustment. A systematic review reported 5.5% intraoperative complications and 6.9% postoperative complications, including 1.9% nonunion, so the gain in durability has to be balanced against a bigger recovery commitment and real operative risk.

Where ChondroFiller fits in the pathway

A different treatment lane opens when the problem is a discrete cartilage lesion in an otherwise still-salvageable knee. In that setting, ChondroFiller is used as a single-stage, acellular collagen scaffold for selected focal defects rather than as a catch-all answer for every painful arthritic joint. Clinic summaries say the evidence base is most mature in the knee, and published series report headline IKDC improvements of about 30 points; even so, those results vary with defect size, defect location, surrounding cartilage quality and overall patient suitability. A knee with widespread, advanced osteoarthritis is therefore usually outside the main ChondroFiller use case.

Mechanical context still matters. A 2012 review of off-loader braces described pain relief by shifting force away from one overloaded compartment with external varus or valgus forces; the same principle helps explain why a focal scaffold is less likely to do well if the knee remains mechanically overloaded. If malalignment or instability keeps driving load through the same area, realignment may need to be addressed first or alongside cartilage repair rather than after it fails.

That is why candidacy is judged on the whole knee, not the defect in isolation: alignment, stability, defect site, arthritis severity, age, BMI and activity goals all shape the plan. Even the manufacturer’s rehabilitation page says its protocol is “only a guide”, which is a useful reminder that restorative cartilage surgery is a different step from symptom control with bracing or injections.

What recovery looks like after ChondroFiller

A practical way to remember the ChondroFiller timeline is protect first, rebuild daily function next, then add higher-load activity cautiously. The exact dates are not tightly standardised in the published literature, and ChondroFiller-specific milestones often come from internal FAQ or manufacturer-style rehabilitation material rather than large peer-reviewed trials, so they are best read as ranges rather than fixed deadlines.

• First 4–6 weeks: this is usually the protection phase. Knee loading is commonly limited, swelling control matters, and movement is kept controlled while the collagen scaffold settles. Internal ChondroFiller guidance describes the material hardening into a gel within 3–5 minutes, but the biological repair process then unfolds much more slowly over the following weeks.
• Around 6–12 weeks: many patients are starting to increase weight-bearing and build strength more deliberately, provided pain and swelling are settling and the surgical plan allows it. This is the stage where physiotherapy typically leans more on muscle control, with cycling and swimming often introduced before anything impact-heavy.
• From about 3 months into the 2–6 month period: the emphasis is usually on steadier day-to-day function rather than a sudden “all clear”. Gym-based control work, longer walks, stairs and other functional loading often become more realistic first; jogging and sport-specific drills may be added later in that window and only in a graded way.

The longer-term point is easy to miss because symptoms may improve before the repair tissue is mature. ChondroFiller material suggests cells migrate into the scaffold over days to weeks, the defect fills over roughly the first 12 months, and remodelling continues as the scaffold is replaced by the patient’s own tissue over about 1–2 years. That biological lag helps explain why feeling better at 3 months does not necessarily mean the knee is ready for unrestricted impact.

What to ask at your assessment

By the time of assessment, the most useful conversation is usually about which problem is actually driving the pain, not which label sounds most advanced. A short checklist helps keep that discussion tied to the knee in front of the clinician.

• Is the main issue “focal cartilage loss”, compartment overload from malalignment, instability, or a combination of the 3?
• If a brace is being suggested, is it intended as a meaningful treatment plan or mainly a “holding measure” before something more definitive?
• If osteotomy is being discussed, is the aim longer-term protection of the knee, or to create the right mechanics for any later cartilage-repair procedure?
• If ChondroFiller is being considered, what would 4–6 weeks, 6–12 weeks, and the 6–12 month period realistically mean for commuting, work, stairs, driving, exercise, and return to sport in this case?

In London, a specialist cartilage and joint-preservation assessment can be arranged through London Cartilage Clinic, Harley Street, via londoncartilage.com; the practical value is in leaving with a clearer map of mechanics, damage pattern, and likely recovery demands.

1. [1] High survivorship rate and good clinical outcomes after high tibial osteotomy in patients with radiological advanced medial knee osteoarthritis: a systematic review. (2024). https://doi.org/10.1007/s00402-024-05254-0 https://doi.org/10.1007/s00402-024-05254-0